Recursion Has Opened 13 Sites for REC-994 Trial
February 15, 2023 –Recursion Pharmaceuticals has twelve US sites enrolling cavernous malformation patients in Phase 2 of their REC-994 Sycamore trial. This is the first industry-sponsored trial of a medicine for cerebral cavernous malformations, a massive milestone toward better treatments. The most recent site to open is Emory University in Atlanta. Please visit our website’s…